Email this article 
Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: A practice standard for Canadian nurses
Abstract
Azacitidine (5-azacytidine, VIDAZA®) is a disease-modifying agent that improves survival, reduces transfusion dependence, and reduces progression to acute myeloid leukemia in patients with higher risk myelodysplastic syndromes. Azacitidine injection is associated with characteristic adverse events (AEs) that must be managed in order for patients to stay on therapy and achieve optimal therapeutic outcomes. These AEs include injection-site reactions, cytopenias, and gastrointestinal effects. Oncology nurses are uniquely positioned to provide patient support and counselling, thereby helping patients and their families set clear expectations for azacitidine therapy. This article presents a nursing standard designed to support Canadian oncology nurses in the key areas of counselling for patients initiating and continuing azacitidine, as well as nursing strategies for prevention and management of azacitidine-associated AEs. Many of the general principles discussed in this nursing standard can be applied broadly to many diseases and treatments.
Full Text:
PDFReferences
Balducci, L. (2006). Transfusion independence in patients with
myelodysplastic syndromes: Impact on outcomes and quality of
life. Cancer, 106(10), 2087–2094.
Bartenstein, M. & Deeg, H.J. (2010). Hematopoietic stem cell
transplantation for MDS. Hematology/Oncology Clinics of North
America, 24(2), 407–422.
Bennett, J. M. (2000). World Health Organization classification of the
acute leukemias and myelodysplastic syndrome. International
Journal of Hematology, 72(2), 131–133.
Buckstein, R., Jang, K., Friedlich, J., Zhang, L., Reis, M., Chesney, A., &
Wells, R. A. (2009). Estimating the prevalence of myelodysplastic
syndromes in patients with unexplained cytopenias: A
retrospective study of 322 bone marrows. Leukemia Research,
(10), 1313–1318.
Buckstein, R., Yee, K., & Wells, R.A.; Canadian Consortium
on Evidence-based Care in MDS. (2011). 5-Azacytidine in
myelodysplastic syndromes: A clinical practice guideline. Cancer
Treatment Reviews, 37(2), 160–167. Epub 2010 Jun 29.
Canadian Association of Nurses in Oncology/Association canadienne
des infirmières en oncologie. (2006). Practice Standards and
Competencies for the Specialized Oncology Nurse.
Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer,
C.A., Nimer, S.D., … Greenberg, P.L. (2000). Report of an
international working group to standardize response criteria for
myelodysplastic syndromes. Blood, 96(12), 3671–3674.
Demakos, E.P. & Linebaugh, J.A. (2005). Advances in myelodysplastic
syndrome: Nursing implications of azacitidine. Clinical Journal of
Oncology Nursing, 9(4), 417–423.
Fenaux, P., Mufti, G.J., Hellström-Lindbert, E., Santini, V., Finelli,
C., Giagounidis, A., … Silverman, L.R., for the International
Vidaza High-Risk MDS Survival Study Group. (2009). Efficacy of
azacitidine compared with that of conventional care regimens
in the treatment of higher-risk myelodysplastic syndromes: A
randomised, open-label, phase III study. The Lancet Oncology,
(3), 223–232.
Gore, S. (2004). Classification, treatment goals, and management
principles for myelodysplastic syndromes. Cancer Control, 11(6
suppl), 3–6.
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz,
G., … Bennett, J. (1997). International scoring system for
evaluating prognosis in myelodysplastic syndromes. Blood, 89(6),
–2088.
Greenberg, P., Tuechler, H., Schanz, J., Sole, F., Bennett, J.M., Garcia-
Manero, G., & Haase, D. (2011). Revised international prognostic
scoring system (IPSS-R), developed by the international
prognostic working group for prognosis in MDS (IWG-PM).
Leukemia Research, 35(s6), Abstract 14.
Haase, D., Germing, U., Schanz, J., Pfellstoker, M., Hildebrandt, B.,
Kundgen, A., … Steidl, C. (2007). New insights into the prognostic
impact of the karyotype in MDS and correlation with subtypes:
Evidence from a core dataset of 2,124 patients. Blood, 110(13),
–4395.
Health Canada. Summary basis of decision for azacitidine
(PrVIDAZA®). (2010). Retrieved from http://www.hc-sc.gc.ca/
dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2010_
vidaza_127108-eng.php
Kindwall-Keller, T., & Isola, L.M. (2009). The evolution of
hematopoietic SCT in myelodysplastic syndrome. Bone Marrow
Transplantation, 43(8), 597–609. Epub 2009 Mar 2.
Kurtin, S., & Demakos, E.P. (2010). An update on the treatment
of myelodysplastic syndromes. Clinical Journal of Oncology
Nursing, 14(3), E29–E44.
Kurzrock, R. (2002). Myelodysplastic syndrome overview. Seminars
in Hematology, 39(3, Suppl. 2), 18–25.
List, A.F., Vardiman, J., Issa, J-P. J., & DeWitte, T.M. (2004).
Myelodysplastic syndromes. Hematology: American Society of
Hematology Education Program, 297–317.
National Cancer Institute. (2011). FDA Approval for Azacitidine.
Retrieved from www.cancer.gov/cancertopics/druginfo/
fda-azacitidine
National Comprehensive Cancer Network (NCCN). (2011). NCCN
Clinical Practice Guidelines in Oncology: Myelodysplastic
Syndromes. V.2. Retrieved from http://www.nccn.org/
professionals/physician_gls/pdf/mds.pdf
Pardo, G., Boutwell, C., Conner, J., Denney, D., & Oleen-Burkey,
M. (2010). Effect of oral antihistamine on local injection site
reactions with self-administered glatiramer acetate. Journal of
Neuroscience Nursing, 42(1), 40–46.
Platzbecker, U., Aul, C., Ehninger, G., & Giagounidis, A. (2010).
Reduction of 5-azacitidine induced skin reactions in MDS
patients with evening primrose oil. Annals of Hematology, 89(4),
–428. Epub 2009 Aug 28.
Santini, V., Fenaux, P., Mufti, J., Ellström-Lindbert, E., Silverman, L.R.,
List, A., … Beach, C.L. (2010). Management and supportive care
measures for adverse events in patients with myelodysplastic
syndromes treated with azacitidine. European Journal of
Haematology, 85(2), 130–138.
VIDAZA® (azacitidine for injection) Product Monograph. Celgene
Inc., Mississauga, Ontario, Canada; May 17, 2012.
Refbacks
- There are currently no refbacks.
